98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1126/science.aea0626 | DOI Listing |
J Radiol Prot
September 2025
Centre for Radiation Protection Research, Stockholm University, Svante Arrheniusväg 20C, 106 91 Stockholm, Sweden.
The System of Radiological Protection (the "System") developed by the International Commission on Radiological Protection (ICRP) is built on nearly a century of efforts of numerous scientists and practitioners working together internationally. It rests on three enduring pillars: science, ethics, and experience. These pillars support the three fundamental principles that shape radiological protection strategies: justification, optimisation, and application of dose limits.
View Article and Find Full Text PDFJ Adolesc
September 2025
California Polytechnic State University, San Luis Obispo, California, USA.
Introduction: The present research examined whether Black and Latine adolescents' academic persistence could be promoted through two novel strength-based reflection activities, providing them an opportunity to experience a sense of school belonging and to form meaningful connections between their racial/ethnic identity and their ideal future identity they aspired for.
Methods: A randomized-controlled experiment was conducted in the U.S.
Trauma Surg Acute Care Open
September 2025
UCHealth, Loveland, Colorado, USA.
Traumatic injury is the leading cause of death for individuals aged 1-45 in the USA. Variations in patient management based on geographic locations, community resources, and provider characteristics contribute to disparities in patient outcomes. It is estimated that 20,000 Americans lives could be saved yearly if all trauma centers performed as well as the highest-performing center, which is achievable, in part, through the reduction of inappropriate practice variation.
View Article and Find Full Text PDFAdv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDFOsteoporos Int
September 2025
International Osteoporosis Foundation, Nyon, Switzerland.
Unlabelled: The study explored osteoporosis patients' views on the disease in six LATAM countries. All were diagnosed for over 3 years, 65% avoiding fragility fractures. Sixteen used osteoporosis drugs, trusting physicians most.
View Article and Find Full Text PDF